How Has the Amebiasis Market Size Evolved in Recent Years?
The amebiasis market has seen considerable growth due to a variety of factors.
• In recent times, the amebiasis market has witnessed robust expansion. The market, valued at $0.82 billion in 2024, is projected to show an increase to $0.88 billion in 2025, recording a compound annual growth rate (CAGR) of 6.9%.
This significant historic growth is credited to multiple factors - a rise in amoebic infections in tropical zones, inadequate sanitation and hygiene habits in developing nations, increased global travel specifically to regions endemic to the disease, heightened awareness about the illness, and the unavailability of purified drinking water in rural communities.
What Are The Predictions for The Amebiasis Market?
The amebiasis market is expected to maintain its strong growth trajectory in upcoming years.
• In the upcoming years, the amebiasis market is predicted to witness significant growth, reaching $1.14 billion in 2029 with a compound annual growth rate (CAGR) of 6.6%.
The projected growth during this period can be accredited to an increase in immune-compromised populations, intensified government efforts to enhance sanitation and healthcare infrastructure, escalated research investment for innovative treatments, heightened focus on health initiatives to fight parasitic diseases, and a rising demand for effective oral medicines. The forecast period is set to see trends such as the widespread adoption of combination therapies, creation of vaccines, progression in drug delivery systems, breakthroughs in pharmaceutical research, and the development of new antiprotozoal drugs.
Which Drivers Are Accelerating Growth In The Amebiasis Market?
The surge in parasitic infection occurrences is projected to fuel the expansion of the amebiasis market in the future. Diseases occurring from parasites like protozoa, helminths, or ectoparasites, which inhabit a host and acquire nutrients at the host's detriment, are referred to as parasitic infections. The rise in instances of such infections is attributed to several factors including increased travel, climate change, inadequate sanitation, and the emergence of drug-resistant strains, all of which collectively aid in the spread and persistence of these infections. The entamoeba histolytica parasite, responsible for amebiasis, adds to these infections by invading the intestines, causing symptoms like diarrhea, abdominal discomfort, and possibly more serious complications like tissue damage and liver abscesses. For example, the Animal and Plant Health Agency, a government agency based in the UK, reported a total of 1,071 parasitic gastroenteritis (PGE) diagnoses in 2022, including 190 instances of haemonchosis and 95 cases of nematodirosis. The count of haemonchosis cases in 2022 was comparatively higher than the year before. Therefore, the surge in parasitic infection instances is promoting the growth of the amebiasis market.
What Are The Core Segments Of The Global Amebiasis Market?
The amebiasis market covered in this report is segmented –
1) By Type: Metronidazole, Paromomycin, Tinidazole
2) By Route Of Administration: Oral, Intravenous
3) By Application: Hospital, Pharmacy
Subsegments:
1) By Metronidazole: Oral Metronidazole, Intravenous Metronidazole, Combination Therapy with Metronidazole
2) By Paromomycin: Oral Paromomycin, Paromomycin in Combination with Other Drugs
3) By Tinidazole: Oral Tinidazole, Tinidazole for Severe Infections
Pre-Book The Amebiasis Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Emerging Trends Are Reshaping The Amebiasis Market Size?
Significant players in the amebiasis market are turning their attention towards the creation of advanced solutions, such as ready-to-use oral liquid metronidazole, to enhance patient adherence and the effectiveness of treatment. The ready-to-use oral liquid metronidazole provides a liquid alternative of the antibiotic used to fight infections like amebiasis, which benefits those patients who struggle with swallowing pills. For example, in November 2023, Kesin Pharma Corporation, a pharmaceutical firm based in the US, acquired approval from the U.S. Food and Drug Administration for its Product Likmez (metronidazole) oral suspension, 500 mg/5 mL, becoming the first company to create a ready-to-use oral liquid version of metronidazole. This oral suspension offers a child-friendly solution, simplifying the process for children to take the medication with the proper dosage, thus ensuring they adhere to the treatment plan more closely. In terms of dosing, the liquid version provides flexibility, enabling medical professionals to modify the treatment as per the individual patient's needs, notably for varying degrees of infection severity.
Who Are the Key Players In The Amebiasis Market?
Major companies operating in the amebiasis market are:
• Pfizer Inc.
• Merck & Co. Inc.
• AbbVie Inc.
• Sanofi SA
• Bristol-Myers Squibb Company
• Thermo Fisher Scientific Inc.
• Novartis AG
• F. Hoffmann-La Roche Ltd
• Eli Lilly and Company
• Takeda Pharmaceutical Company Limited
• Boehringer Ingelheim International GmbH
• Siemens Healthineers AG
• Becton Dickinson and Company
• Teva Pharmaceutical Industries Ltd.
• Cipla Limited
• Hikma Pharmaceuticals PLC
• Lupin Limited
• Cepheid Inc.
• Mission Pharmacal Company
• Profounda Inc.
• Zydus Lifesciences Limited
What Are The Regional Insights Into The Amebiasis Market?
North America was the largest region in the amebiasis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the amebiasis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
